Hepion Pharmaceuticals (HEPA) Stock Forecast, Price Target & Predictions
HEPA Stock Forecast
Hepion Pharmaceuticals stock forecast is as follows: an average price target of $70.00 (represents a 9385.09% upside from HEPA’s last price of $0.74) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
HEPA Price Target
HEPA Analyst Ratings
Hepion Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Mar 01, 2022 | Kristen Kluska | Cantor Fitzgerald | $70.00 | $24.60 | 184.55% | 9385.09% |
Hepion Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.74 | $0.74 | $0.74 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Mar 01, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Hepion Pharmaceuticals Financial Forecast
Hepion Pharmaceuticals Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
---|---|---|---|---|
Revenue | - | - | - | - |
Avg Forecast | - | - | - | $1.16B |
High Forecast | - | - | - | $1.39B |
Low Forecast | - | - | - | $928.38M |
# Analysts | - | - | - | 15 |
Surprise % | - | - | - | - |
Hepion Pharmaceuticals EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
---|---|---|---|---|
# Analysts | - | - | - | 15 |
EBITDA | - | - | - | $-1.80M |
Avg Forecast | - | - | - | $-2.23M |
High Forecast | - | - | - | $-1.78M |
Low Forecast | - | - | - | $-2.68M |
Surprise % | - | - | - | 0.81% |
Hepion Pharmaceuticals Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
---|---|---|---|---|
# Analysts | - | - | - | 15 |
Net Income | - | - | - | $-1.73M |
Avg Forecast | $-11.42M | $-11.02M | $-21.51M | $-2.13M |
High Forecast | $-11.42M | $-11.02M | $-21.51M | $-1.71M |
Low Forecast | $-11.42M | $-11.02M | $-21.51M | $-2.56M |
Surprise % | - | - | - | 0.81% |
Hepion Pharmaceuticals SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
---|---|---|---|---|
# Analysts | - | - | - | 15 |
SG&A | - | - | - | $1.06M |
Avg Forecast | - | - | - | $1.25M |
High Forecast | - | - | - | $1.50M |
Low Forecast | - | - | - | $997.58K |
Surprise % | - | - | - | 0.85% |
Hepion Pharmaceuticals EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Sep 19 | |
---|---|---|---|---|
# Analysts | - | - | - | 15 |
EPS | - | - | - | $-0.50 |
Avg Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.75 |
High Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.60 |
Low Forecast | $-1.97 | $-1.90 | $-3.71 | $-0.90 |
Surprise % | - | - | - | 0.67% |
HEPA Forecast FAQ
Is Hepion Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Hepion Pharmaceuticals (HEPA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of HEPA's total ratings.
What is HEPA's price target?
Hepion Pharmaceuticals (HEPA) average price target is $70 with a range of $70 to $70, implying a 9385.09% from its last price of $0.738. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Hepion Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for HEPA stock, the company can go up by 9385.09% (from the last price of $0.738 to the average price target of $70), up by 9385.09% based on the highest stock price target, and up by 9385.09% based on the lowest stock price target.
Can Hepion Pharmaceuticals stock reach $1?
HEPA's average twelve months analyst stock price target of $70 supports the claim that Hepion Pharmaceuticals can reach $1 in the near future.
What are Hepion Pharmaceuticals's analysts' financial forecasts?
HEPA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-43.957M (high $-43.957M, low $-43.957M), average SG&A $0 (high $0, low $0), and average EPS is $-7.58 (high $-7.58, low $-7.58).